285 related articles for article (PubMed ID: 25659907)
21. Vitronectin binding to urokinase receptor in human breast cancer.
Carriero MV; Del Vecchio S; Franco P; Potena MI; Chiaradonna F; Botti G; Stoppelli MP; Salvatore M
Clin Cancer Res; 1997 Aug; 3(8):1299-308. PubMed ID: 9815812
[TBL] [Abstract][Full Text] [Related]
22. Rational targeting of the urokinase receptor (uPAR): development of antagonists and non-invasive imaging probes.
Kriegbaum MC; Persson M; Haldager L; Alpízar-Alpízar W; Jacobsen B; Gårdsvoll H; Kjær A; Ploug M
Curr Drug Targets; 2011 Nov; 12(12):1711-28. PubMed ID: 21707479
[TBL] [Abstract][Full Text] [Related]
23. Variability in the expression of urokinase receptor (CD87) mutants on cells: relevance to cell adhesion.
Kanse SM; Chavakis T; Kuo A; Bdeir K; Cines DB; Preissner KT
Cell Biochem Funct; 2004; 22(4):257-64. PubMed ID: 15248186
[TBL] [Abstract][Full Text] [Related]
24. Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes.
Huai Q; Zhou A; Lin L; Mazar AP; Parry GC; Callahan J; Shaw DE; Furie B; Furie BC; Huang M
Nat Struct Mol Biol; 2008 Apr; 15(4):422-3. PubMed ID: 18376415
[TBL] [Abstract][Full Text] [Related]
25. Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin.
Deng G; Curriden SA; Hu G; Czekay RP; Loskutoff DJ
J Cell Physiol; 2001 Oct; 189(1):23-33. PubMed ID: 11573201
[TBL] [Abstract][Full Text] [Related]
26. The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction.
Høyer-Hansen G; Behrendt N; Ploug M; Danø K; Preissner KT
FEBS Lett; 1997 Dec; 420(1):79-85. PubMed ID: 9450554
[TBL] [Abstract][Full Text] [Related]
27. Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy.
Lin L; Gårdsvoll H; Huai Q; Huang M; Ploug M
J Biol Chem; 2010 Apr; 285(14):10982-92. PubMed ID: 20133942
[TBL] [Abstract][Full Text] [Related]
28. Did evolution create a flexible ligand-binding cavity in the urokinase receptor through deletion of a plesiotypic disulfide bond?
Leth JM; Mertens HDT; Leth-Espensen KZ; Jørgensen TJD; Ploug M
J Biol Chem; 2019 May; 294(18):7403-7418. PubMed ID: 30894413
[TBL] [Abstract][Full Text] [Related]
29. Plasminogen activator inhibitors regulate cell adhesion through a uPAR-dependent mechanism.
Czekay RP; Loskutoff DJ
J Cell Physiol; 2009 Sep; 220(3):655-63. PubMed ID: 19472211
[TBL] [Abstract][Full Text] [Related]
30. A flexible multidomain structure drives the function of the urokinase-type plasminogen activator receptor (uPAR).
Mertens HD; Kjaergaard M; Mysling S; Gårdsvoll H; Jørgensen TJ; Svergun DI; Ploug M
J Biol Chem; 2012 Oct; 287(41):34304-15. PubMed ID: 22896701
[TBL] [Abstract][Full Text] [Related]
31. Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (αM).
Xu X; Cai Y; Wei Y; Donate F; Juarez J; Parry G; Chen L; Meehan EJ; Ahn RW; Ugolkov A; Dubrovskyi O; O'Halloran TV; Huang M; Mazar AP
PLoS One; 2014; 9(1):e85349. PubMed ID: 24465541
[TBL] [Abstract][Full Text] [Related]
32. Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor.
Ploug M; Ellis V; Danø K
Biochemistry; 1994 Aug; 33(30):8991-7. PubMed ID: 8043585
[TBL] [Abstract][Full Text] [Related]
33. Intermolecular contact regions in urokinase plasminogen activator receptor.
Liang OD; Bdeir K; Matz RL; Chavakis T; Preissner KT
J Biochem; 2003 Nov; 134(5):661-6. PubMed ID: 14688231
[TBL] [Abstract][Full Text] [Related]
34. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue.
Luther T; Magdolen V; Albrecht S; Kasper M; Riemer C; Kessler H; Graeff H; Müller M; Schmitt M
Am J Pathol; 1997 Apr; 150(4):1231-44. PubMed ID: 9094980
[TBL] [Abstract][Full Text] [Related]
35. Mapping part of the functional epitope for ligand binding on the receptor for urokinase-type plasminogen activator by site-directed mutagenesis.
Gårdsvoll H; Danø K; Ploug M
J Biol Chem; 1999 Dec; 274(53):37995-8003. PubMed ID: 10608868
[TBL] [Abstract][Full Text] [Related]
36. Disulfide bonding arrangements in active forms of the somatomedin B domain of human vitronectin.
Kamikubo Y; De Guzman R; Kroon G; Curriden S; Neels JG; Churchill MJ; Dawson P; Ołdziej S; Jagielska A; Scheraga HA; Loskutoff DJ; Dyson HJ
Biochemistry; 2004 Jun; 43(21):6519-34. PubMed ID: 15157085
[TBL] [Abstract][Full Text] [Related]
37. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
Pass J; Jögi A; Lund IK; Rønø B; Rasch MG; Gårdsvoll H; Lund LR; Ploug M; Rømer J; Danø K; Høyer-Hansen G
Thromb Haemost; 2007 Jun; 97(6):1013-22. PubMed ID: 17549305
[TBL] [Abstract][Full Text] [Related]
38. A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor.
Hillig T; Engelholm LH; Ingvarsen S; Madsen DH; Gårdsvoll H; Larsen JK; Ploug M; Danø K; Kjøller L; Behrendt N
J Biol Chem; 2008 May; 283(22):15217-23. PubMed ID: 18362146
[TBL] [Abstract][Full Text] [Related]
39. Ab initio molecular orbital calculations on specific interactions between urokinase-type plasminogen activator and its receptor.
Nagase K; Kobayashi H; Yoshikawa E; Kurita N
J Mol Graph Model; 2009 Aug; 28(1):46-53. PubMed ID: 19403319
[TBL] [Abstract][Full Text] [Related]
40. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
